Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center “real-life” cohort

BACKGROUND: The combination of sofosbuvir (SOF), ribavirin (RBV) and peg-interferon-alfa-2a (peg-IFN-alfa-2a) as well as the combination of SOF and RBV for the treatment of patients infected with hepatitis c virus (HCV) has improved rates of sustained virological response (SVR) considerably in recen...

Descripción completa

Detalles Bibliográficos
Autores principales: Steinebrunner, Niels, Sprinzl, Martin F., Zimmermann, Tim, Wörns, Marcus A., Zimmerer, Thomas, Galle, Peter R., Stremmel, Wolfgang, Eisenbach, Christoph, Stein, Kerstin, Antoni, Christoph, Schattenberg, Jörn M., Pathil, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523924/
https://www.ncbi.nlm.nih.gov/pubmed/26239732
http://dx.doi.org/10.1186/s12876-015-0328-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523924/
https://www.ncbi.nlm.nih.gov/pubmed/26239732
http://dx.doi.org/10.1186/s12876-015-0328-9

Ejemplares similares